Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders

#2924

Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.

Aim(s): The aim of this study was to determine the rate of long responders to everolimus and their tolerability and efficacy.

Materials and methods: Retrospective analysis of advanced, progressive NENs treated with Everolimus . Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th – 75th IQR).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, De Felice I, Magi L, Prosperi D, Iannicelli E,

Keywords: everolimus, neuroendocrine neoplasia, progressive disease, target therapy,